Pre-existing humoral immunity against seasonal coronaviruses enhances antibody responses on SARS-CoV-2 vaccination

Clicks: 1
ID: 313505
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #98 of 208 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background High homology and cross-reactive immune responses between SARS-CoV-2 and seasonal human coronaviruses (HCoVs) have been reported. However, the impact of pre-existing immunity against seasonal HCoVs on SARS-CoV-2 vaccination is undetermined. Methods We conducted a cross-sectional study involving pediatric and adult participants between August 2020 and August 2023. IgG titers against SARS-CoV-2 and seasonal HCoV-229E, -HKU1, -NL63, and -OC43 were quantified by electrochemiluminescent immunoassay. A paired analysis was performed in a subset of participants with samples collected before and after SARS-CoV-2 vaccination. Results N=1,804 participants (median age: 44 years; range: 2-95) were enrolled. IgG titers against HCoV-229E, -HKU1, and -OC43 increased during early childhood. Among SARS-CoV-2-vaccinated participants without prior SARS-CoV-2 infection, anti-spike IgG titers against SARS-CoV-2 positively correlated with titers against HCoV-OC43, -HKU1, and -NL63 (Spearman r=0.40, 0.26, and 0.12; P <0.0001, <0.0001, and 0.0002). In paired analysis, participants with high baseline HCoV-HKU1 and -OC43 IgG titers developed higher post-vaccination anti-SARS-CoV-2 spike IgG responses than those with low baseline titers (geometric mean [AU/mL]: 111,384 vs. 54,610 and 113,279 vs. 50,099; P=0.03 and 0.015). Multivariable linear regression analyses demonstrated that baseline HCoV-HKU1 and -OC43 IgG titers remained independently associated with post-vaccination anti–SARS-CoV-2 spike IgG levels (β=110,592 and 108,855; 95%CI, 17,922–203,262 and 12,013–205,697; P=0.020 and 0.028). Conclusion Higher baseline immunity to HCoV-HKU1 and -OC43 was associated with stronger SARS-CoV-2 vaccine–induced antibody responses. These findings suggest that pre-existing immunity against seasonal betacoronaviruses may enhance humoral immune response to SARS-CoV-2 vaccination.
Reference Key
openalex_W7161157431 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Etsuro Nanishi, Matthew Hwang, Ana Citlali Márquez, Walter Byrne, Maria-Rosa La Neve, Alice Litosh, Jasmik S Saini, Kimberly Thompson, Nicole Wisener, Makiko Nanishi, Julia E M Upton, Aaron Campigotto, Michelle Barton, Agatha N. Jassem, Upton Allen
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag232
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.